StockData
Biodexa Pharmaceuticals Plc logo

Biodexa Pharmaceuticals Plc (BDRX) stock

BDRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 27, 2026Score 1/30
$2.24−0.16 (-6.67%)

Close on Nov 16, 2026Market cap $5.06MP/E –Yield –

Biodexa Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Biodexa Pharmaceuticals's price to sales ratio was 8.8× on Feb 28, 2025, against 0.7× a year earlier. Over the last 5 years it ranged from 0.7× to 490.2×, with a median of 71.5×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Feb 28, 20258.8×−2.0
2024Dec 31, 202410.7×+9.2
2023Dec 29, 20231.5×−336.2
2021Jan 29, 2021337.7×+39.9
2020Dec 31, 2020297.8×+265.0
2019Dec 31, 201932.8×−93.3
2018Dec 31, 2018126.0×−211.5
2017Dec 29, 2017337.6×–

More Biodexa Pharmaceuticals figures

See a number that looks wrong?